Georgia House Bill HB931

Georgia 2025-2026 Regular Session

• Introduced: 4/4/25

Caption

Health; control high costs of prescription drugs; establish framework

Impact

The bill's implications are significant as it addresses concerns regarding the equity and sustainability of healthcare access among various demographics, particularly underserved communities. By potentially lowering out-of-pocket costs for consumers, the board's decisions could directly affect individuals' ability to afford necessary treatments. The legislation additionally aims to control the financial burden on state-funded healthcare programs, suggesting that the high cost of prescription drugs adversely impacts the state’s finances as it relates to public services and programs.

Summary

House Bill 931 aims to mitigate the rising costs of prescription drugs in Georgia by establishing a regulatory framework that includes the creation of the Prescription Drug Affordability Board. This board is tasked with conducting affordability reviews of certain prescription drugs, which can lead to setting upper payment limits on drugs identified as unaffordable. The legislation emphasizes the importance of access to affordable medications for maintaining health and is built upon legislative findings that high drug costs threaten both public health and economic stability for residents in Georgia.

Contention

While the bill is a step towards accountability and affordability in drug pricing, it might face opposition from pharmaceutical companies and stakeholders concerned about the regulation's impact on market dynamics and innovation. Establishing price limits could discourage investment in new drug development or lead to shortages in the market. Critics might argue that the bill, while aiming to reduce drug costs, does not adequately address the root causes of high pharmaceutical prices, such as research and development costs and market monopolies. The effectiveness of the Prescription Drug Affordability Board in navigating these complexities will be crucial in determining the overall success of the bill.